Klisyri (Tirbanibulin) Patent Expiration, LOE Window & CMS Spending

Klisyri (Tirbanibulin) by Almirall: FDA Orange Book core substance LOE 2038-09-07, 0 AB generics, $3.4M 2024 CMS Part D & Medicaid spend, and $1,556 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmirall
FDA Application & PathwayN213189 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-09-07
Last Listed Patent or Exclusivity Date2038-09-07
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.4M
2024 Medicare Part D Spend$3.4M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,556 intro WAC)